IDEAS home Printed from https://ideas.repec.org/p/osf/lawarx/6cxaj.html
   My bibliography  Save this paper

The TRIPS Article 31 Tug of War Developing Country Compulsory Licensing of Pharmaceutical Patents and Developed Country Retaliation

Author

Listed:
  • Volman, Lucas

Abstract

My dissertation examines compulsory licensing under Article 31 of the TRIPS Agreement by looking at the use of such licensing by developing countries, as well as retaliatory and restrictive measures imposed by developed countries. In doing so, it looks at the right to health, and price and intellectual property considerations for access to medicines in developing countries. It further explores the TRIPS compulsory licensing rules themselves to present compulsory licensing as a legitimate, and at times necessary, policy measure under international law. Then, it examines how compulsory licensing has been used and restricted since TRIPS, and how the compulsory licence relates to voluntary licensing and international free trade agreements, both of which are factors for the development of compulsory licensing strategies in developing countries.

Suggested Citation

  • Volman, Lucas, 2018. "The TRIPS Article 31 Tug of War Developing Country Compulsory Licensing of Pharmaceutical Patents and Developed Country Retaliation," LawArXiv 6cxaj, Center for Open Science.
  • Handle: RePEc:osf:lawarx:6cxaj
    DOI: 10.31219/osf.io/6cxaj
    as

    Download full text from publisher

    File URL: https://osf.io/download/5b4ddac4778458000d070441/
    Download Restriction: no

    File URL: https://libkey.io/10.31219/osf.io/6cxaj?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    References listed on IDEAS

    as
    1. Tommaso M. Valletti & Stefan Szymanski, 2006. "Parallel Trade, International Exhaustion And Intellectual Property Rights: A Welfare Analysis," Journal of Industrial Economics, Wiley Blackwell, vol. 54(4), pages 499-526, December.
    2. Ciuriak , Dan & Xiao, Jingliang & Dadkhah, Ali, 2017. "Quantifying the Comprehensive and Progressive Agreement for Trans-Pacific Partnership," East Asian Economic Review, Korea Institute for International Economic Policy, vol. 21(4), pages 343-384, December.
    3. Henry Grabowski, 2002. "Patents, Innovation and Access to New Pharmaceuticals," Journal of International Economic Law, Oxford University Press, vol. 5(4), pages 849-860, December.
    4. Frederick M. Abbott, 2002. "The Doha Declaration on the TRIPS Agreement and Public Health: Lighting a Dark Corner at the WTO," Journal of International Economic Law, Oxford University Press, vol. 5(2), pages 469-505, July.
    5. Eric W. Bond & Kamal Saggi, 2023. "Compulsory licensing, price controls, and access to patented foreign products," World Scientific Book Chapters, in: Kamal Saggi (ed.), Technology Transfer, Foreign Direct Investment, and the Protection of Intellectual Property in the Global Economy, chapter 19, pages 437-448, World Scientific Publishing Co. Pte. Ltd..
    6. Grabowski, Henry, 2002. "Patents, Innovation and Access to New Pharmaceuticals," Working Papers 02-28, Duke University, Department of Economics.
    7. repec:adr:anecst:y:1998:i:49-50:p:19 is not listed on IDEAS
    8. F. M. Scherer, 1998. "The Size Distribution of Profits from Innovation," Annals of Economics and Statistics, GENES, issue 49-50, pages 495-516.
    9. Jon Sussex & Adrian Towse & Nancy Devlin, 2013. "Operationalizing Value-Based Pricing of Medicines," PharmacoEconomics, Springer, vol. 31(1), pages 1-10, January.
    10. Joseph Golec & John A. Vernon, 2007. "New estimates of pharmaceutical research and development spending by US-based firms from 1984 to 2003," Managerial and Decision Economics, John Wiley & Sons, Ltd., vol. 28(4-5), pages 481-483.
    11. A. P. Thirlwall, 2013. "Economic Growth in an Open Developing Economy," Books, Edward Elgar Publishing, number 15208.
    12. Bale, Harvey, Jr, 1998. "The Conflicts between Parallel Trade and Product Access and Innovation: The Case of Pharmaceuticals," Journal of International Economic Law, Oxford University Press, vol. 1(4), pages 637-653, December.
    13. Margaret K. Kyle, 2007. "Pharmaceutical Price Controls and Entry Strategies," The Review of Economics and Statistics, MIT Press, vol. 89(1), pages 88-99, February.
    14. Charan Devereaux & Robert Z. Lawrence & Michael D. Watkins, 2006. "Case Studies in US Trade Negotiation: Resolving Disputes, Vol. 2," Peterson Institute Press: All Books, Peterson Institute for International Economics, number 3634, April.
    15. Ramani, Shyama V. & Urias, Eduardo, 2018. "When access to drugs meets catch-up: Insights from the use of CL threats to improve access to ARV drugs in Brazil," Research Policy, Elsevier, vol. 47(8), pages 1538-1552.
    16. Charan Devereaux & Robert Z. Lawrence & Michael D. Watkins, 2006. "Case Studies in US Trade Negotiation, 2-volume set," Peterson Institute Press: All Books, Peterson Institute for International Economics, number 3640, April.
    17. Ramani, Shyama V. & Urias, Eduardo, 2015. "Access to critical medicines: When are compulsory licenses effective in price negotiations?," Social Science & Medicine, Elsevier, vol. 135(C), pages 75-83.
    18. Jean O. Lanjouw, 2005. "Patents, Price Controls and Access to New Drugs: How Policy Affects Global Market Entry," Working Papers 61, Center for Global Development.
    19. Jillian Clare Cohen & Kristina M. Lybecker, 2005. "AIDS Policy and Pharmaceutical Patents: Brazil's Strategy to Safeguard Public Health," The World Economy, Wiley Blackwell, vol. 28(2), pages 211-230, February.
    20. Cohen-Kohler, Jillian Clare & Forman, Lisa & Lipkus, Nathaniel, 2008. "Addressing legal and political barriers to global pharmaceutical access: Options for remedying the impact of the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) and the impo," Health Economics, Policy and Law, Cambridge University Press, vol. 3(3), pages 229-256, July.
    21. Mazzoleni, Roberto & Nelson, Richard R., 1998. "The benefits and costs of strong patent protection: a contribution to the current debate," Research Policy, Elsevier, vol. 27(3), pages 273-284, July.
    22. Charan Devereaux & Robert Z. Lawrence & Michael D. Watkins, 2006. "Case Studies in US Trade Negotiation: Making the Rules, Vol. 1," Peterson Institute Press: All Books, Peterson Institute for International Economics, number 392, April.
    23. Yamin, A.E., 2005. "The right to health under international law and its relevance to the United States," American Journal of Public Health, American Public Health Association, vol. 95(7), pages 1156-1161.
    24. Charitini Stavropoulou & Tommaso Valletti, 2015. "Compulsory licensing and access to drugs," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 16(1), pages 83-94, January.
    25. Oecd, 2002. "Access for Business," OECD Digital Economy Papers 67, OECD Publishing.
    26. Giovanni Dosi & Joseph Stiglitz, 2013. "The Role of Intellectual Property Rights in the Development Process, with Some Lessons from Developed Countries: An Introduction," LEM Papers Series 2013/23, Laboratory of Economics and Management (LEM), Sant'Anna School of Advanced Studies, Pisa, Italy.
    27. Akaleephan, Chutima & Wibulpolprasert, Suwit & Sakulbumrungsil, Rungpetch & Luangruangrong, Paithip & Jitraknathee, Anchalee & Aeksaengsri, Achara & Udomaksorn, Siripa & Tangcharoensathien, Viroj & Ta, 2009. "Extension of market exclusivity and its impact on the accessibility to essential medicines, and drug expense in Thailand: Analysis of the effect of TRIPs-Plus proposal," Health Policy, Elsevier, vol. 91(2), pages 174-182, July.
    28. Suzanne Zhou, 2016. "Challenging the Use of Special 301 against Measures Promoting Access to Medicines: Options Under the WTO Agreements," Journal of International Economic Law, Oxford University Press, vol. 19(1), pages 51-86.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Kamal Saggi, 2016. "Trade, Intellectual Property Rights, and the World Trade Organization," Vanderbilt University Department of Economics Working Papers 16-00014, Vanderbilt University Department of Economics.
    2. Damien Besancenot & Samira Guennif, 2024. "Compulsory license threats in a signaling game of drug procurement," Theory and Decision, Springer, vol. 97(2), pages 261-298, September.
    3. Sarmah, Archita & De Giovanni, Domenico & De Giovanni, Pietro, 2020. "Compulsory licenses in the pharmaceutical industry: Pricing and R&D strategies," European Journal of Operational Research, Elsevier, vol. 282(3), pages 1053-1069.
    4. Eric W Bond & Kamal Saggi, 2017. "Price controls versus compulsory licensing: effects on patent-holders and consumers," Vanderbilt University Department of Economics Working Papers 17-00013, Vanderbilt University Department of Economics.
    5. Lorenz, Steffi, 2015. "Diversität und Verbundenheit der unternehmerischen Wissensbasis: Ein neuartiger Messansatz mit Indikatoren aus Innovationsprojekten," Discussion Papers on Strategy and Innovation 15-01, Philipps-University Marburg, Department of Technology and Innovation Management (TIM).
    6. Eric W. Bond & Kamal Saggi, 2023. "Compulsory licensing, price controls, and access to patented foreign products," World Scientific Book Chapters, in: Kamal Saggi (ed.), Technology Transfer, Foreign Direct Investment, and the Protection of Intellectual Property in the Global Economy, chapter 19, pages 437-448, World Scientific Publishing Co. Pte. Ltd..
    7. Nebibe Varol & Joan Costa-i-Font & Alistair McGuire, 2011. "Explaining Early Adoption on New Medicines: Regulation, Innovation and Scale," CESifo Working Paper Series 3459, CESifo.
    8. Luiz Andrade & Catherine Sermet & Sylvain Pichetti, 2016. "Entry time effects and follow-on drug competition," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 17(1), pages 45-60, January.
    9. Patricia M. Danzon & Eric L. Keuffel, 2014. "Regulation of the Pharmaceutical-Biotechnology Industry," NBER Chapters, in: Economic Regulation and Its Reform: What Have We Learned?, pages 407-484, National Bureau of Economic Research, Inc.
    10. Eric W. Bond & Kamal Saggi, 2023. "Patent protection in developing countries and global welfare: WTO obligations versus flexibilities," World Scientific Book Chapters, in: Kamal Saggi (ed.), Technology Transfer, Foreign Direct Investment, and the Protection of Intellectual Property in the Global Economy, chapter 22, pages 505-520, World Scientific Publishing Co. Pte. Ltd..
    11. Chatterjee, Chirantan & Kubo, Kensuke & Pingali, Viswanath, 2015. "The consumer welfare implications of governmental policies and firm strategy in markets for medicines," Journal of Health Economics, Elsevier, vol. 44(C), pages 255-273.
    12. Nicolas Houy & Izabela Jelovac, 2014. "Drug approval decision times, international reference pricing and strategic launches of new drugs," Working Papers halshs-01072741, HAL.
    13. Brekke, Kurt R. & Holmås, Tor Helge & Straume, Odd Rune, 2015. "Price regulation and parallel imports of pharmaceuticals," Journal of Public Economics, Elsevier, vol. 129(C), pages 92-105.
    14. Patricia M. Danzon & Andrew J. Epstein, 2012. "Effects of Regulation on Drug Launch and Pricing in Interdependent Markets," Advances in Health Economics and Health Services Research, in: The Economics of Medical Technology, pages 35-71, Emerald Group Publishing Limited.
    15. Neel U. Sukhatme & Judd N. L. Cramer, 2013. "Optimal Patent Term and Cross-Industry Measures of Patent Term Sensitivity," Working Papers 1484, Princeton University, Department of Economics, Industrial Relations Section..
    16. Santanu Roy & Kamal Saggi, 2023. "Equilibrium parallel import policies and international market structure," World Scientific Book Chapters, in: Kamal Saggi (ed.), Technology Transfer, Foreign Direct Investment, and the Protection of Intellectual Property in the Global Economy, chapter 15, pages 349-363, World Scientific Publishing Co. Pte. Ltd..
    17. Verniers, Isabel & Stremersch, Stefan & Croux, Christophe, 2011. "The global entry of new pharmaceuticals: A joint investigation of launch window and price," International Journal of Research in Marketing, Elsevier, vol. 28(4), pages 295-308.
    18. Eric W. Bond & Kamal Saggi, 2023. "Bargaining over Entry with a Compulsory License Deadline: Price Spillovers and Surplus Expansion," World Scientific Book Chapters, in: Kamal Saggi (ed.), Technology Transfer, Foreign Direct Investment, and the Protection of Intellectual Property in the Global Economy, chapter 20, pages 449-480, World Scientific Publishing Co. Pte. Ltd..
    19. Nicolas Houy & Izabela Jelovac, 2015. "Drug Launch Timing and International Reference Pricing," Health Economics, John Wiley & Sons, Ltd., vol. 24(8), pages 978-989, August.
    20. Abdulkadir Civan & Michael Maloney, 2017. "Launch Decisions of Pharmaceutical Companies," Journal of Economics and Financial Analysis, Tripal Publishing House, vol. 1(1), pages 35-58.

    More about this item

    NEP fields

    This paper has been announced in the following NEP Reports:

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:osf:lawarx:6cxaj. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: OSF (email available below). General contact details of provider: https://osf.io/preprints/lawarxiv/discover .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.